News

June 17, 2021

Cytovale Aiming to Enter Sepsis Testing Market With Rapid, Direct-From-Blood, Point-of-Care Platform

Diagnostic test developer Cytovale this month took a step closer to its goal of commercializing a host-response test that has the potential to provide an assessment for the risk of sepsis in 10 minutes.

Read More
April 30, 2020

BARDA, Cytovale launch study to diagnose sepsis in patients with COVID-19

Cytovale Inc. will expand its partnership with the Biomedical Advanced Research and Development Authority, or BARDA, to examine the use of Cytovale’s Rapid Sepsis Diagnostic System for diagnosing sepsis in patients with potential respiratory infections, including COVID-19, according to a press release.

Read More
April 27, 2020

BARDA Offers Additional Funding for Cytovale’s Rapid-Sepsis Diagnostic Study

Cytovale has received $3.8 million from HHS Biomedical Advanced Research and Development Authority (BARDA) for a study of its rapid-sepsis test for COVID-19 patients.

Read More
July 15, 2018

Rapid Biophysical Analysis of Host Immune Cell Variations Associated with Sepsis

Early, rapid diagnosis is critical to more effective identification and treatment of sepsis. We measured shifts in the biomechanical properties of immune cells, specifically activated neutrophils, in patients with sepsis using a new deformability cytometry technique.

Read More

Publications

Additional Publications

Press

Additional Resources

Small Scientific Journal

Focusing Cells to Single Streams

Read More
Microsystems & Nanoengineering

Biophysical Classification of Cell Differentiation State

Read More
Nature - Scientific Reports

Introducing the Cell Mechanome

Read More
Annual Review of Biomedical Engineering

New Opportunities for Rapid Mechanical Measurement of Cells

Read More
Current Opinion in Biotechnology

Advances in high-throughput single-cell microtechnologies

Read More
Do you have an application for our technology?

Contact Us